In summary, our results suggest that targeting p/CIP and SRC-1 may not only reduce obesity but also enhance glucose uptake and insulin sensitivity, which would offer benefits not obtained by using TZDs for treatment of diabetes. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.